

Curriculum Vitae

Peng Cheng-Yuan (彭成元)

Education:

M.D. (1981-1988), College of Medicine, National Taiwan University, Taiwan

Ph.D. (1992-1997), Committee on Virology, Division of Medical Sciences, Harvard University, USA

Academic Appointment:

1. 1997-2001 Assistant Professor, Graduate Institute of Clinical Medicine, Chang Gung University
2. 2001-2002 Assistant Professor, Department of Chinese Medicine, Chang Gung University
3. 2002-2012 Assistant Professor, Department of Medicine, China Medical University
4. 2012- Associate Professor, Department of Medicine, China Medical University

Professional Experience:

1. 1988-1989 Resident in Department of Medicine, Cathay General Hospital, Taipei, Taiwan
2. 1989-1992 Resident in Department of Medicine, National Taiwan University Hospital, Taipei, Taiwan
3. 1997-1999 Fellow in Division of Hepatogastroenterology, Department of Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan
4. 1999-2002 Attending Physician in Division of Hepatogastroenterology, Department of Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan
5. 2002-2003 Attending Physician in Division of Hepatogastroenterology, Department of Medicine, China Medical University Hospital, Taichung, Taiwan
6. 2003-2016 Chief of Division of Gastroenterology, Department of Medicine, China Medical University Hospital, Taichung, Taiwan
7. 2016-present Director of Digestive Medicine, Department of Medicine, China Medical University Hospital, Taichung, Taiwan

Research Interest:

1. Host and viral factors in the pathogenesis of chronic hepatitis B
2. Liver fibrosis and its regression in chronic hepatitis B and C
3. Clinical and experimental therapy of chronic hepatitis B and C

Honors and Award:

1. 1992-1997 Full Scholarship, Harvard University, USA
2. 1998 Research Award, National Science Council, Taiwan

3. 2002 Young Investigator Award of the Year, Biennial Scientific Meeting of the Asian Pacific Association for the Study of the Liver, 2000-2002
4. 2012 The 63rd Annual Meeting of the American Association for the Study of Liver Diseases: Presidential Poster of Distinction
5. 2013 The 64th Annual Meeting of the American Association for the Study of Liver Diseases: Presidential Poster of Distinction
6. 2016 臺灣醫學會雜誌杜聰明博士優秀論文獎

Journal Reviewer:

Gastroenterology; Journal of Hepatology; Clinical Gastroenterology and Hepatology; Alimentary Pharmacology and Therapeutics; Journal of Antimicrobial Chemotherapy; Liver International; Journal of Gastroenterology; Journal of Viral Hepatitis; Journal of Gastroenterology and Hepatology; Hepatology International; World Journal of Gastroenterology; Annals of Gastroenterology; Annals of Hepatology; Scientific Reports; Medicine; Molecular Biology Reports; Journal of Translational Medicine; Journal of Biomedical Science; Journal of the Formosan Medical Association; The Kaohsiung Journal of Medical Sciences; Journal of International Cooperation; African Journal of Microbiology Research; African Journal of Pharmacy and Pharmacology; Drug Design, Development and Therapy; Drugs; Case Reports in Oncological Medicine; Advances in Digestive Medicine.

Publications:

1. Peng CY, Tsai W*. *Isospora belli* infection in a patient with Hodgkin's disease: report of a case. *J Formosan Med Assoc* 1991; 90: 260-263.
2. Atherton-Fessler S, Liu F, Gabrielli B, Lee MS, Peng CY, Piwnica-Worms H*. Cell cycle regulation of the p34cdc2 inhibitory kinases. *Mol Biol Cell* 1994; 5: 989-1001.
3. Xu M, Sheppard KA, Peng CY, Yee AS, Piwnica-Worms H*. Cyclin A/cdk2 binds directly to E2F-1 and inhibits the DNA-binding activity of E2F-1/DP-1 by phosphorylation. *Mol Cell Biol* 1994; 14: 8420-8431.
4. Peng CY, Graves PR, Thoma RS, Wu Z, Shaw AS, Piwnica-Worms H*. Mitotic and G2 checkpoint control: regulation of 14-3-3 protein binding by phosphorylation of Cdc25C on serine-216. *Science* 1997; 277: 1501-1505.
5. Peng CY, Graves PR, Ogg S, Thoma RS, Byrnes MJ III, Wu Z, Stephenson M, Piwnica-Worms H*. C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. *Cell Growth Differ* 1998; 9: 197-208.
6. Peng CY, Tsai SL, Yeh CT, Hung SP, Chen MF, Chen TC, Chu CM, Liaw YF*. Genetic alterations of p73 are infrequent but may occur in early stage hepatocellular carcinoma. *Anticancer Research* 2000; 20: 1487-1492.
7. Tai DI, Tsai SL*, Chen YM, Chuang YL, Peng CY, Shen IS, Yeh CT, Chang KSS, Huang SN, Kuo GC, Liaw YF. Activation of nuclear factor kB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. *Hepatology* 2000; 31: 656-664.
8. Yeh CT*, Lu SC, Chen TC, Peng CY, Liaw YF. Aberrant transcripts of the cyclin dependent kinase-associated protein phosphatase in hepatocellular carcinoma. *Cancer Research* 2000; 60: 4697-4700.
9. Peng CY*, Chen TC, Hung SP, Chen MF, Yeh CT, Tsai SL, Chu CM, Liaw YF.

- Genetic alterations of *INK4a/ARF* locus and p53 in human hepatocellular carcinoma. *Anticancer Research* 2002; 22: 1265-1272.
10. Lin SM*, Shen CH, Lin DY, Kuo SH, Lin CJ, Hsu CW, Chung HJ, Peng CY. Cytologic changes in small hepatocellular carcinomas after radiofrequency ablation. *Acta Cytologica* 2002; 46: 490-494.
 11. Lin SM*, Lin CJ, Chung HJ, Hsu CW, Peng CY. Power rolloff during interactive radiofrequency ablation can enhance necrosis when treating hepatocellular carcinoma. *AJR* 2003; 180: 151-157.
 12. Chen TW, Peng CY, Hsu CH, Yao CC, Chiang IP. Carcinoid tumor of the jejunum with perforation. *Mid-Taiwan J Medicine* 2003; 8: 48-52.
 13. Chou JW, Hsu CH, Peng CY, Yung MD, Ho YJ, Chiang IP. Hemobilia caused by a ruptured pseudoaneurysm of hepatic artery: report of a case. *Gastroenterological J Taiwan* 2004; 21: 147-154.
 14. Huang WH, Wu WW, Wang HH, Chiang EP, Hsu CH, Peng CY. Inflammatory fibroid polyp of the pylorus: report of a case. *Gastroenterological J Taiwan* 2004; 21: 255-262.
 15. Chen CB, Lai HC, Peng CY, Jeng LB, Ho YJ, Chiang IP. Primary hepatic carcinoid tumor: report of a case. *Gastroenterological J Taiwan* 2005; 22: 129-135.
 16. Lai HC, Chan CY, Peng CY, Chen CB, Huang WH. Pyogenic liver abscess associated with large colonic tubulovillous adenoma. *World J Gastroenterol* 2006; 12: 990-992.
 17. Lee TH, Tai DI, Cheng CJ, Sun CS, Lin CY, Sheu MJ, Lee WP, Peng CY, Wang AH, Tsai SL*. Enhanced nuclear factor-kappa B-associated Wnt-1 expression in hepatitis B- and C-related hepatocarcinogenesis: identification by functional proteomics. *J Biomed Sci* 2006; 13: 27-39.
 18. Liao KF, Peng CY, Lai SW*, Chang WL, Hsu NY. Descriptive epidemiology of hepatitis C virus among male heroin abusers in Taiwan. *Southern Med J* 2006; 99: 348-351.
 19. Chou JW, Hsu CH, Liao KF, Lai HC, Cheng KS, Peng CY, Yang MD, Chen YF. Gallstone ileus: report of two cases and review of the literature. *World J Gastroenterol* 2007; 13: 1295-1298.
 20. Lai SW, Chang WL, Peng CY, Liao KF*. Viral hepatitis among male amphetamine-inhaling abusers. *Intern Med J* 2007; 37: 472-477.
 21. Wu PL, Liao KF, Peng CY, Pariante CM, Su KP*. Manic episode associated with citalopram therapy for interferon-induced depression in a patient with chronic hepatitis C infection. *Gen Hosp Psychiatry* 2007; 29: 374-376.
 22. Tseng YC, Tseng CK, Chou JW, Lai HC, Hsu CH, Cheng KS, Peng CY, Chen YF. A rare cause of mesenteric ischemia: celiac axis compression syndrome. *Intern Med* 2007; 46: 1187-1190.
 23. Tsai CC, Chou JW, Chiang IP, Lai HC, Peng CY. Mesenteric phleboscrosis. *Intern Med* 2008; 47: 183-184.
 24. Chen SH, Huang WH*, Feng CL, Chou JW, Hsu CH, Peng CY, Yang MD. Clinical analysis of ectopic pancreas with endoscopic ultrasonography: an experience in a medical center. *J Gastrointest Surg* 2008; 12: 877-881.
 25. Tseng CK, Su WB, Lai HC, Chou JW, Feng CL, Peng CY, Chen YF. Superior mesenteric artery syndrome caused by celiac axis compression syndrome: a case report and review of the literature. *Eur J Gastroenterol Hepatol* 2008; 20: 578-582.

26. Chang SC, Ko WS, Wu SS*, Peng CY, Yang SS. Factors associated with quality of life in chronic hepatitis C patients who received interferon plus ribavirin therapy. *J Formos Med Assoc* 2008; 107: 454-462.
27. Chou JW, Feng CL, Lai HC, Tsai CC, Chen SH, Hsu CH, Cheng KS, Peng CY, Chung PK. Obscure gastrointestinal bleeding caused by small bowel lipoma. *Intern Med* 2008; 47: 1601-1603.
28. Chou JW, Yu CJ, Chuang PH, Lai HC, Hsu CH, Cheng KS, Peng CY, Chiang IP. Successful treatment of fosinopril-induced severe cholestatic jaundice with plasma exchange. *Ann Pharmacother* 2008; 42: 1887-1892.
29. Huang WH*, Peng CY, Yu CJ, Chou JW, Feng CL. Endoloop-assisted unroofing for the treatment of symptomatic duodenal lipomas. *Gastrointest Endosc* 2008; 68: 1234-1236.
30. Leung N*, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. *Hepatology* 2009; 49: 72-79.
31. Wan L, Kung YJ, Lin YJ, Liao CC, Sheu JJ, Tsai Y, Lai HC, Peng CY*, Tsai FJ*. Th1 and Th2 cytokines are elevated in HCV-infected SVR(-) patients treated with interferon-alpha. *Biochem Biophys Res Commun* 2009; 379: 855-860.
(* corresponding author)
32. Liu CJ, Lee PH, Lin DY, Wu CC, Jeng LB, Lin PW, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Lee CC, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ*. Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. *J Hepatol* 2009; 50: 958-968.
33. Su WP, Peng CY*, Lai HC, Liao KF, Huang WH, Chuang PH, Chen CB, Jeng LB. Persistent transaminase elevations in chronic hepatitis C patients with virological response during peginterferon and ribavirin therapy. *Hepatogastroenterology* 2009; 56: 798-801. (* corresponding author)
34. Chainuvati S, Cheng J, Hou JL, Hsu CW, Jia JD, Komolmit P, Kwon SY, Lee CH, Li H, Li Y, Liu CJ, Neo BL, Peng CY, Tanwandee T, Wongcharatrawee S, Wu JC, Yu ML, Zhang XX. Patterns of managing chronic hepatitis B treatment-related drug resistance: a survey of physicians in Mainland China, South Korea, Taiwan, and Thailand. *Hepatol Int* 2009; 3: 453-460.
35. Yu CJ, Wang HH, Chou JW, Lai HC, Huang WH, Peng CY, Cheng KS, Chen YF. Phlebosclerotic colitis with nonsurgical treatment. *Int J Colorectal Dis* 2009; 24: 1241-1242.
36. Lai HC, Tsai CC, Feng CL, Yu CJ, Chou JW, Huang WH, Hsu CH, Cheng KS, Peng CY. Epigastric pain in a man with previous subtotal gastrectomy. *Gut* 2009; 58: 1332.
37. Su KP, Huang SY, Peng CY, Lai HC, Huang CL, Chen YC, Aitchison KJ, Pariante CM. Phospholipase A2 and cyclooxygenase 2 genes influence the risk of interferon-alpha-induced depression by regulating polyunsaturated fatty acids levels. *Biol Psychiatry* 2010; 67: 550-557.
38. Huang WH*, Feng CL, Lai HC, Yu CJ, Chou JW, Peng CY, Yang MD, Chiang IP. Endoscopic ligation and resection for the treatment of small EUS-suspected gastric

- GI stromal tumors. *Gastrointest Endosc* 2010; 71: 1076-1081.
39. Peng CY*, Chen CB, Lai HC, Su WP, Chuang PH, Wu HI, Jeng LB. Predictors for early HBeAg loss during lamivudine therapy in HBeAg-positive chronic hepatitis B patients with acute exacerbation. *Hepatol Int* 2011; 5: 586-596.
 40. Lin YN, Chou JW*, Chuang PH, Cheng KS, Peng CY, Chiang IP. Primary small intestinal natural killer/T cell lymphoma mimicking tuberculous peritonitis: report of a case and review of the literature. *Intern Med* 2011; 50: 515-518.
 41. Patel K*, Thompson AJ, Chuang WL, Lee CM, Peng CY, Shanmuganathan G, Thongsawat S, Tanwandee T, Mahachai V, Pramoolsinsap C, Cho M, Han KH, Shah SR, Foster GR, Clark PJ, Pulkstenis E, Subramanian GM, McHutchison JG. Insulin resistance is independently associated with significant hepatic fibrosis in Asian chronic hepatitis C genotype 2 or 3 patients. *J Gastroenterol Hepatol* 2011; 26: 1182-1188.
 42. Liaw YF*, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS Jr, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized open-label study. *Hepatology* 2011; 54: 91-100.
 43. Huang WH*, Lin TY, Peng CY. Chronic skin ulcer revealing metastasis from gastric cancer. *Clin Gastroenterol Hepatol* 2011; 9: e86-87.
 44. Han EC, Lee YS, Liu YC, Liao HY, Liao WS, Lai HC, Peng CY*, Jeng LB. Mass spectrometry-based plasma peptide profiling of acute exacerbation in HBeAg-positive chronic hepatitis B. *Clin Chim Acta* 2011; 412: 2174-2182.
(*corresponding author)
 45. Peng CY*, Lai HC, Li YF, Su WP, Chuang PH, Kao JT. Early serum HBsAg level as a strong predictor of sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. *Aliment Pharmacol Ther* 2012; 35: 458-468. (*corresponding author)
 46. Poon KS, Chen TH, Jeng LB*, Yang HR, Li PC, Lee CC, Yeh CC, Lai HC, Su WP, Peng CY, Chen YF, Ho YJ, Tsai PP. A high model for end-stage liver disease score should not be considered a contraindication to living donor liver transplantation. *Transplant Proc* 2012; 44: 316-319.
 47. Li PC, Jeng LB*, Yang HR, Lee CC, Poon KS, Chen TH, Yeh CC, Lai HC, Su WP, Peng CY, Chen YF, Ho YJ. Hepatic artery reconstruction in living donor liver transplantation: running suture under surgical loupes by cardiovascular surgeons in 180 recipients. *Transplant Proc* 2012; 44: 448-450.
 48. Yang HR, Jeng LB*, Li PC, Lee CC, Poon KS, Chen TH, Yeh CC, Lai HC, Su WP, Peng CY, Chen YF, Ho YJ. Living donor right hepatectomy with inclusion of the middle hepatic vein: outcome in 200 donors. *Transplant Proc* 2012; 44: 460-462.
 49. Soh KS, Jeng LB*, Yang HR, Li PC, Lee CC, Poon KS, Chen TH, Yeh CC, Lai HC, Su WP, Peng CY, Chen YF, Ho YJ. Simultaneous liver and kidney transplantation from different living donors. *Transplant Proc* 2012; 44: 509-511.
 50. Chen SH, Li YF, Lai HC, Kao JT, Peng CY*, Chuang PH, Su WP, Chiang IP. Noninvasive assessment of liver fibrosis via spleen stiffness measurement using acoustic radiation force impulse sonoelastography in patients with chronic hepatitis B or C. *J Viral Hepat* 2012; 19: 654-663. (*corresponding author)
 51. Peng CY*. Commentary: HBsAg levels as predictor of sustained response to

- peginterferon in HBeAg-negative chronic hepatitis B – author's reply. *Aliment Pharmacol Ther* 2012; 35: 843-844. (*corresponding author)
52. Peng CY, Chien RN, Liaw YF*. Hepatitis B virus-related decompensated liver disease: benefits of antiviral therapy. *J Hepatol* 2012; 57: 442-450. (*corresponding author)
53. Chen SH, Li YF, Lai HC, Kao JT, Peng CY*, Chuang PH, Su WP, Chiang IP. Effects of patient factors on noninvasive liver stiffness measurement using acoustic radiation force impulse elastography in patients with chronic hepatitis C. *BMC Gastroenterology* 2012; 12: 105. (*corresponding author)
54. Lim YP, Tsai FJ, Liao WL, Tien N, Hung DZ, Peng CY*, Wan L*. Association of genetic variations in GNB1 with response to peginterferon plus ribavirin therapy for chronic hepatitis C in a Chinese population in Taiwan. *BMC Gastroenterology* 2012; 12: 167. (*corresponding author)
55. Wang CC, Tseng KC, Peng CY, Hsieh TY, Lin CL, Su TH, Tseng TC, Hsu CS, Lin HH, Kao JH*. Viral load and ALT correlate with serologic response in chronic hepatitis B patients treated with entecavir. *J Gastroenterol Hepatol* 2013; 28: 46-50.
56. Yuan Q, Song LW, Liu CJ, Li Z, Liu PG, Huang CH, Yan Y, Ge SX, Wang YB, Peng CY, Zhang J*, Kao JH, Chen DS, Chen PJ, Xia NS. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. *Gut* 2013; 62: 182-184.
57. Yang HC, Chen CL, Shen YC, Peng CY, Liu CJ, Tseng TC, Su TH, Chuang WL, Yu ML, Dai CY, Liu CH, Chen PJ, Chen DS, Kao JH*. Distinct evolution and predictive value of hepatitis B virus precore and basal core promoter mutations in interferon-induced HBeAg seroconversion. *Hepatology* 2013; 57: 934-943.
58. Lai HC, Tsai IJ, Chen PC, Muo CH, Chou JW, Peng CY, Lai SW, Sung FC, Lyu SY*, Morisky DE. Gallstones, a cholecystectomy, chronic pancreatitis, and the risk of subsequent pancreatic cancer in diabetic patients: a population-based cohort study. *J Gastroenterol* 2013; 48: 721-727.
59. Lai HC, Chang SN, Lin CC, Chen CC, Chou JW, Peng CY, Lai SW, Sung FC, Li YF*. Does diabetes mellitus with or without gallstones increase the risk of gallbladder cancer? Results from a population-based cohort study. *J Gastroenterol* 2013; 48: 856-865.
60. Lim YP, Peng CY, Liao WL, Hung DZ, Tien N, Chen CY, Chang SY, Chang CY, Tsai FJ*, Wan L*. Genetic variation in NOS2A is associated with a sustained virological response to peginterferon plus ribavirin therapy for chronic hepatitis C in Taiwanese Chinese. *J Med Virol* 2013; 85: 1206-1214.
61. Lim YP, Hsu YA, Tsai KH, Tsai FJ*, Peng CY, Liao WL, Hung DZ, Tien N, Lin CY*, Wan L*. The impact of polymorphisms in STAT6 on treatment outcome in HCV infected Taiwanese Chinese. *BMC Immunol* 2013; 14: 21.
62. Lin T, Ibrahim W, Peng CY, Finegold MJ, Tsai RY*. A novel role of nucleostemin in maintaining the genome integrity of dividing hepatocytes during mouse liver development and regeneration. *Hepatology* 2013; 58: 2176-2187.
63. Lai HC, Lin CC, Cheng KS, Kao JT, Chou JW, Peng CY, Lai SW, Chen PC, Sung FC*. Increased incidence of gastrointestinal cancers among patients with pyogenic liver abscess: a population-based cohort study. *Gastroenterology* 2014; 146: 129-137.
64. Chien RN, Peng CY, Kao JH, Hu TH, Lin CC, Hu CT, Chen CY, Hsieh TY, Lin HC,

- Chuang WL*, and Taiwan NA Registry Group. Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B. *J Gastroenterol Hepatol* 2014; 29: 185-192.
65. Lee CM, Chen CY, Chien RN, Tseng KC, Peng CY, Tung SY, Fang YJ, Huang YH, Lu SN, Hung CH, Tsai TJ, Fang CC, Hsu CW, Yeh CT*. A double-blind randomized controlled study to evaluate the efficacy of low-dose oral interferon-alpha in preventing hepatitis C relapse. *J Interferon Cytokine Res* 2014; 34: 187-194.
66. Peng CY, Chen TH, Lim YP, Tsai FJ*, Lin WY, Liao WL, Wan L*. Association of MRC-1 and IL-28B with the treatment outcome of hepatitis C: a case control study. *BMC Gastroenterology* 2014; 14: 113.
67. Liu CJ, Chang J, Lee PH, Lin DY, Wu CC, Jeng LB, Lin YJ, Mok KT, Lee WC, Yeh HZ, Ho MC, Yang SS, Yang MD, Yu MC, Hu RH, Peng CY, Lai KL, Chang SS, Chen PJ*. Adjuvant heparanase inhibitor PI-88 therapy for hepatocellular carcinoma recurrence. *World J Gastroenterol* 2014; 20: 11384-11393.
68. Su KP, Lai HC, Yang HT, Su WP, Peng CY, Chang JP, Chang HC, Pariante CM*. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. *Biol Psychiatry* 2014; 76: 559-566.
69. Manns M*, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. *Lancet* 2014; 384: 1597-1605.
70. Marcellin P*, Wursthorn K, Wedemeyer H, Chuang WL, Lau G, Avila C, Peng CY, Gane E, Lim SG, Fainboim H, Foster GR, Safadi R, Rizzetto M, Manns M, Bao W, Naoumov N. Telbivudine plus pegylated interferon alfa-2a in a randomized study in chronic hepatitis B was associated with unexpected high rate of peripheral neuropathy. *J Hepatol* 2015; 62: 41-47.
71. Jeng LB*, Thorat A, Yang HR, Yeh CC, Chen TH, Hsu CH, Hsu SC, Poon KS, Li PC, Lai HC, Su WP, Peng CY. Successful use of hepatitis B surface antigen-positive liver grafts- an effective source for donor organs in endemic areas: a single-center experience. *Ann Transplant* 2015; 20: 103-111.
72. Chen SH, Peng CY*, Lai HC, Su WP, Lin CH, Li YF, Chuang PH, Chen CH. An index to predict ribavirin-induced anemia in Asian patients with chronic genotype 1 hepatitis C. *Hepat Mon* 2015; 15: e27148. (*corresponding author)
73. Peng CY, Hsieh TC, Hsieh TY, Tseng KC, Lin CL, Su TH, Tseng TC, Lin HH, Wang CC*, Kao JH*. HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients. *J Formos Med Assoc* 2015; 114: 308-313.
74. Yeh ML*, Peng CY*, Dai CY, Lai HC, Huang CF, Hsieh MY, Huang JF, Chen SC, Lin ZY, Yu ML, Chuang WL. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients. *PLoS One* 2015; 10: e0122259. (*equal contribution)
75. Pawlotsky JM, Flisiak R, Sarin SK, Rasenack J, Piratvisuth T, Chuang WL, Peng CY, Foster GR, Shah S, Wedemeyer H, Hézode C, Zhang W, Wong KA, Li B, Avila C, Naoumov NV. Alisporivir plus ribavirin, interferon-free or in combination with peg-interferon, for HCV genotype 2 or 3 infection. *Hepatology* 2015; 62:

- 1013-1023.
76. Chen SH, Peng CY*, Lai HC, Chang IP, Lee CJ, Su WP, Lin CH, Kao JT, Chuang PH. Head-to-head comparison between collagen proportionate area and acoustic radiation force impulse elastography in liver fibrosis quantification in chronic hepatitis C. *PLoS One* 2015; 10: e0140554. (*corresponding author)
 77. Chen YC, Peng CY, Jeng WJ, Chien RN, Liaw YF*. Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. *Aliment Pharmacol Ther* 2015; 42: 1182-1191.
 78. Yang CC, Tsai WL, Su WW, Huang CF, Cheng PN, Lo CC, Tseng KC, Mo LR, Wang CH, Hsu SJ, Lai HC, Su CW, Liu CJ, Peng CY, Yu ML*. Rapid prediction of treatment futility of boceprevir with peginterferon-ribavirin for Taiwanese treatment experienced hepatitis C virus genotype 1-infected patients. *PLoS One* 2015; 10: e0137852.
 79. Wang CC, Lin CL, Hsieh TY, Tseng KC, Peng CY, Su TH, Yang SS, Hsu YC, Chen TM, Kao JH*. Efficacy and resistance to telbivudine treatment in chronic hepatitis B patients with favorable predictors: a multicenter study in Taiwan. *Hepatol Int* 2016; 10: 294-301.
 80. Lin WY, Peng CY, Lin CC, Davidson LE, Pi-Sunyer FX, Sung PK, Huang KC. General and abdominal adiposity and risk of death in HBV versus non-HBV carriers: a 10-year population-based cohort study. *Medicine* 2016; 95: e2162.
 81. Chan HL, Ahn SH, Chang TT, Peng CY, Wong D, Coffin CS, Lim SG, Chen PJ, Janssen H, Marcellin P, Serfaty L, Zeuzem S, Cohen D, Critelli L, Xu D, Wind-Rotolo M, Cooney E*. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B). *J Hepatol* 2016; 64: 1011-1019.
 82. Hsiao WD, Peng CY, Chuang PH, Lai HC, Cheng KS, Chou JW, Chen YY, Yu CJ, Feng CL, Su WP, Chen SH, Kao JT*. Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study. *BMC Gastroenterol* 2016; 16: 50.
 83. Tseng KC, Tseng CW, Hsieh TY, Peng CY, Lin CL, Su TH, Tseng TC, Lin HH, Wang CC*, Kao JH*. Efficacy of entecavir therapy for HBeAg-positive chronic hepatitis B patients with prior exposure to interferon or nucleos(t)ide analogues. *Hepatol Res* 2016; 46: 642-649.
 84. Chuang WL, Chien RN, Peng CY, Chang TT, Lo GH, Sheen IS, Wang HY, Chen JJ, Yang JC, Knox SJ, Gao B, Garrison KL, Mo H, Pang PS, Hsu YC, Hu TH, Chu CJ, Kao JH*. Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus. *J Gastroenterol Hepatol* 2016; 31: 1323-1329.
 85. Kao JH, Jensen DM, Manns MP, Jacobson I, Kumada H, Toyota J, Heo J, Yoffe B, Sievert W, Bessone F, Peng CY, Roberts SK, Lee YJ, Bhore R, Mendez P, Hughes E, Noviello S*. Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. *Liver Int* 2016; 36: 954-962.
 86. Hsiao PJ, Hsieh PF, Chou EC*, Lai HC*, Peng CY, Su KP. Anti-viral therapy and decreased sexual desire in patients with chronic hepatitis C. *PLoS One* 2016; 11: e0160450.
 87. Chen SH, Peng CY*, Chiang IP, Lai HC, Lee CJ, Su WP, Kao JT, Chuang PH.

- Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C. *Medicine* 2016; 95: e4736. (*corresponding author)
88. Kao JH, Chien RN, Chang TT, Peng CY, Hu TH, Lo GH, Wang HY, Chen JJ, Yang JC, Knox SJ, Han L, Mo H, Mathias A, Brainard DM, Sheen IS, Hsu YC, Chu CJ, Chuang WL*. A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection. *Liver Int* 2016; 36: 1101-1107.
 89. Chen DS*, Liaw YF, Chen CJ, Wu JC, Chuang WL, Peng CY, Chien RN. Differences in hepatitis viral etiology of hepatocellular carcinoma in Taiwan and China. *Hepatology* 2016; 64: 1008-1009.
 90. Kao JH*, Lee YJ, Heo J, Ahn SH, Lim YS, Peng CY, Chang TT, Torbeyns A, Hughes E, Bhoire R, Noviello S. All-oral daclatasvir plus asunaprevir for chronic HCV genotype 1b infection: a sub-analysis in Asian patients from the HALLMARK DUAL study. *Liver Int* 2016; 36: 1433-1441.
 91. Chang JP, Lai HC, Yang HT, Su WP, Peng CY, Gałecki P, Walczewska A, Pariante CM, Su KP*. Polyunsaturated fatty acids levels and initial presentation of somatic symptoms induced by interferon-alpha therapy in patients with chronic hepatitis C viral infection. *Nutr Neurosci* (Epub 28 Dec 2015).
 92. Lai YL, Kuo YC, Lai HC, Peng CY, Wang YC, Liang JA, Chen SW*. Early radiation-induced liver toxicities are associated with poor survival in patients with advanced hepatocellular carcinoma. *Asia Pac J Clin Oncol* (Epub 07 Mar 2016).
 93. Dore GJ*, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. Elbasvir-Grazoprevir to treat hepatitis C virus infection in persons receiving opioid agonist therapy: a randomized trial. *Ann Intern Med* (Epub 09 Aug 2016).
 94. Su TH, Hu TH, Chen CY, Huang YH, Chuang WL, Lin CC, Wang CC, Su WW, Chen MY, Peng CY, Chien RN, Huang YW, Wang HY, Lin CL, Yang SS, Chen TM, Mo LR, Hsu SJ, Tseng KC, Hsieh TY, Suk FM, Hu CT, Bair MJ, Liang CC, Lei YC, Tseng TC, Chen CL, Kao JH*; C-TEAM study group and the Taiwan Liver Diseases Consortium. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. *Liver Int* (16 Sep 2016).